Chiesi announces phase 3 results from enzyme-replacement study
Natalia Elliot | October 29, 2024 | News story | Research and Development | Internal Medicine, Rare Diseases, chiesi Global rare diseases, clinical trials, pharma, rare diseases
Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug ELFABRIO at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (ELFABRIO) is 1miligramg (mg) per kilogram (kg) administered every two weeks.
The BRIGHT study, which was completed over the course of 52 weeks, contained 29 patients – only 21% of which were female. Results demonstrated that 30% of patients experienced at least one adverse reaction, which was mild or moderate. No patients developed novo anti-drug antibodies or treatment-emergent AEs which would have lead to an study discontinuation or mortality.
“We are pleased to share that the Journal of Inherited Metabolic Disease has published these data from this phase 3, open-label, multinational, switchover study evaluating the pharmacokinetics, safety and efficacy of 2 mg/kg ELFABRIO administered every four weeks,” said Giacomo Chiesi, executive vice president of Chiesi Global Rare Diseases. “Chiesi is committed to evaluating additional evidence to confirm the long-term results of this administration schedule.”
Fabry disease is a rare X-linked lysosomal disorder that results in excessive deposition of lipids in the tissues. Young patients usually present with stroke, skin lesions, heart attack, or renal failure.
“Fabry disease today is witnessing the surge of innovative research into diverse treatments, which is a new dawn of hope rising on the horizon,” said Jack Johnson, vice president, Americas & Global, Fabry International Network and co-founder, executive director Fabry Disease Support & Information Group.
Natalia Elliot
29/10/24
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
